Pharmaceuticals, Biotechnology and Life Sciences
Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).
Former Pfizer CEO and chairman Jeff Kindler will be joining privately held Israel’s drugmaker Pharma Two B’s board of directors, as the company completed its third round of financing, raising $30 million, with Israel Biotech Fund (IBF) leading the procedure. Jeff Kindler is a member of Israel Biotech Fund’s Venture Advisory Team.
Allergan’s Vice President of Investor Relations, Lisa DeFrancesco, has resign after being nearly 8 years of leading the Investor Relations of the company.
Argenx and Shire have extended their strategic partnership from 2014 to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.
Valeant Pharmaceuticals`s subsidiary, Bausch + Lomb, and Nicox have resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for latanoprostene bunod ophthalmic solution, 0.024%.
According to Verona Pharma’s CEO, Dr. Jan-Anders Karlsson, the highlights of 2016 were encouraging clinical data for RPL554, additional financing from “a very experienced syndicate” of investors, and further strengthening of the company’s Board and executive team.
Premaitha Health, an international molecular diagnostics group focused on prenatal testing, has acquired Taiwanese Yourgene Bioscience.
Midatech has borrowed £6 million from Silicn Valley Bank to add to the placing of the shares it made in October last year.
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.
CTI BioPharma has appointed Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors